---
document_datetime: 2025-11-14 15:47:50
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/comirnaty-epar-all-authorised-presentations_en.pdf
document_name: comirnaty-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 2.9535387
conversion_datetime: 2025-12-28 10:49:08.23249
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                      | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size                                      |
|------------------|-------------------|------------|------------------------------------------|---------------------------|----------------------------|---------------------------|------------------------------------------------|
| EU/1/20/1528/028 | COMIRNATY JN.1    | -- 15      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 0.48 ml (1 dose)          | 10 single dose vials (10 doses)                |
| EU/1/20/1528/029 | COMIRNATY JN.1    | -- 15      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 2.25 ml (6 doses)         | 10 multidose vials (60 doses)                  |
| EU/1/20/1528/030 | COMIRNATY JN.1    | -- 15      | Dispersion for injection                 | Intramuscular use         | pre-filled syringe (glass) | 0.418 ml (1 dose)         | 10 pre-filled syringes (10 doses); fridge only |
| EU/1/20/1528/032 | COMIRNATY JN.1    | -- 16      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 0.48 ml (1 dose)          | 10 single dose vials (10 doses)                |
| EU/1/20/1528/033 | COMIRNATY JN.1    | -- 16      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 2.25 ml (6 doses)         | 10 multidose vials (60 doses)                  |
| EU/1/20/1528/034 | COMIRNATY JN.1    | -- 17      | Concentrate for dispersion for injection | Intramuscular use         | vial (glass)               | 1.3 ml (10 doses)         | 10 multidose vials (100 doses)                 |
| EU/1/20/1528/035 | COMIRNATY JN.1    | -- 18      | Concentrate for dispersion for injection | Intramuscular use         | vial (glass)               | 0.48 ml (3 doses)         | 10 multidose vials (30 doses)                  |
| EU/1/20/1528/036 | COMIRNATY JN.1    | -- 19      | Concentrate for dispersion for injection | Intramuscular use         | vial (glass)               | 0.4 ml (10 doses)         | 10 multidose vials (100 doses)                 |
| EU/1/20/1528/037 | COMIRNATY KP.2    | -- 20      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 0.48 ml (1 dose)          | 10 single dose vials (10 doses)                |
| EU/1/20/1528/038 | COMIRNATY KP.2    | -- 20      | Dispersion for injection                 | Intramuscular use         | vial (glass)               | 2.25 ml (6 doses)         | 10 multidose vials (60 doses)                  |
| EU/1/20/1528/039 | COMIRNATY KP.2    | -- 20      | Dispersion for injection                 | Intramuscular use         | pre-filled syringe (glass) | 0.418 ml (1 dose)         | 10 pre-filled syringes (10 doses); fridge only |

<div style=\"page-break-after: always\"></div>

| EU/1/20/1528/040   | COMIRNATY KP.2   | -- 21   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 0.48 ml (1 dose)   | 10 single dose vials (10 doses)             |
|--------------------|------------------|---------|------------------------------------------|---------------------|----------------------------|--------------------|---------------------------------------------|
| EU/1/20/1528/041   | COMIRNATY KP.2   | -- 21   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses)               |
| EU/1/20/1528/042   | COMIRNATY KP.2   | -- 22   | Concentrate for dispersion for injection | Intramuscular use   | vial (glass)               | 0.48 ml (3 doses)  | 10 multidose vials (30 doses)               |
| EU/1/20/1528/043   | COMIRNATY JN.1   | -- 15   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses); fridge only  |
| EU/1/20/1528/044   | COMIRNATY KP.2   | -- 20   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses); fridge only  |
| EU/1/20/1528/045   | COMIRNATY LP.8.1 | -- 23   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses)               |
| EU/1/20/1528/046   | COMIRNATY LP.8.1 | -- 23   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses); fridge only  |
| EU/1/20/1528/047   | COMIRNATY LP.8.1 | -- 23   | Dispersion for injection                 | Intramuscular use   | pre-filled syringe (glass) | 0.418 ml (1 dose)  | 10 pre-filled syringes (10 doses);          |
| EU/1/20/1528/048   | COMIRNATY LP.8.1 | -- 24   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 0.48 ml (1 dose)   | fridge only 10 single dose vials (10 doses) |
| EU/1/20/1528/049   | COMIRNATY LP.8.1 | -- 24   | Dispersion for injection                 | Intramuscular use   | vial (glass)               | 2.25 ml (6 doses)  | 10 multidose vials (60 doses)               |
| EU/1/20/1528/050   | COMIRNATY LP.8.1 | -- 25   | Concentrate for dispersion for injection | Intramuscular use   | vial (glass)               | 0.48 ml (3 doses)  | 10 multidose vials (30 doses)               |
| EU/1/20/1528/051   | COMIRNATY LP.8.1 | -- 23   | Dispersion for injection                 | Intramuscular use   | pre-filled syringe (glass) | 0.418 ml (1 dose)  | 1 pre-filled syringe                        |

<div style=\"page-break-after: always\"></div>

(1 dose); fridge only

-- 15 : COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-030, EU/1/20/1528/043):

1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

-- 16 : COMIRNATY JN.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/032-033):

1 dose (0.3 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

-- 17 : COMIRNATY JN.1 10 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/034):

After dilution, 1 dose (0.2 mL) contains 10 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

-- 18 : COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/035):

After dilution, 1 dose (0.3 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

-- 19 : COMIRNATY JN.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/036):

After dilution, 1 dose (0.2 mL) contains 3 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Bretovameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1).

-- 20 : COMIRNATY KP.2 30 micrograms/dose dispersion for injection (EU/1/20/1528/037-039, EU/1/20/1528/044):

1 dose (0.3 mL) contains 30 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

<div style=\"page-break-after: always\"></div>

-- 21 : COMIRNATY KP.2 10 micrograms/dose dispersion for injection (EU/1/20/1528/040-041):

1 dose (0.3 mL) contains 10 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

-- 22 : COMIRNATY KP.2 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/042):

After dilution, 1 dose (0.3 mL) contains 3 micrograms of cemivameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

Cemivameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron KP.2).

-- 23 : COMIRNATY LP.8.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/045-047, EU/1/20/1528/051):

1 dose (0.3 mL) contains 30 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).

-- 24 : COMIRNATY LP.8.1 10 micrograms/dose dispersion for injection (EU/1/20/1528/048-049):

1 dose (0.3 mL) contains 10 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).

-- 25 : COMIRNATY LP.8.1 3 micrograms/dose concentrate for dispersion for injection (EU/1/20/1528/050):

After dilution, 1 dose (0.3 mL) contains 3 micrograms mRNA encoding LP.8.1, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles).

The mRNA encoding LP.8.1 is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron LP.8.1).